Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL), a specialized company in advanced therapies for sports medicine and severe burn care, has announced its participation in the upcoming Bank of America Securities 2025 Healthcare Conference. The presentation is scheduled for Wednesday, May 14, 2025, at 12:20 p.m. ET (9:20 a.m. PT). Investors and interested parties can access the presentation webcast through the company's investor relations website at http://investors.vcel.com.

News Market Reaction – VCEL

+5.25%

+5.25% Session move

In the trading session that priced this news, VCEL gained 5.25%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 Healthcare Conference at 12:20 p.m. ET (9:20 a.m. PT) on Wednesday, May 14, 2025.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

FAQ

When is Vericel (VCEL) presenting at the Bank of America Healthcare Conference 2025?

Vericel will present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025, at 12:20 p.m. ET (9:20 a.m. PT).

How can investors watch Vericel's (VCEL) presentation at the Bank of America Healthcare Conference?

Investors can watch the presentation via webcast on Vericel's Investor Relations website at http://investors.vcel.com.

What markets does Vericel Corporation (VCEL) specialize in?

Vericel Corporation specializes in advanced therapies for the sports medicine and severe burn care markets.